Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q3SXY7
UPID:
LRIT3_HUMAN
Alternative names:
-
Alternative UPACC:
Q3SXY7; C9J1C2; Q6ZTG1
Background:
Leucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containing protein 3 plays a crucial role in the visual system. It facilitates synaptic transmission between cone photoreceptor cells and retinal bipolar cells, essential for processing light-evoked stimuli. This protein is pivotal for the localization of the TRPM1 cation channel in retinal ON-bipolar cells and influences cone synapse formation.
Therapeutic significance:
Linked to congenital stationary night blindness, understanding the function of this protein could pave the way for innovative treatments for visual impairments. Its involvement in synaptic transmission and cone synapse formation highlights its potential as a therapeutic target.